Exelixis doubles down on ADCs for cancer with NBE, Catalent dealsExelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug Share XExelixis doubles down on ADCs for cancer with NBE, Catalent dealshttps://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/
Catalent acquires gene therapy specialist Paragon for $1.2bnDrug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. Paragon specialises in Share XCatalent acquires gene therapy specialist Paragon for $1.2bnhttps://pharmaphorum.com/news/catalent-acquires-gene-therapy-paragon/
